Literature DB >> 1312121

The nucleotide sequences of wild-type coxsackievirus A9 strains imply that an RGD motif in VP1 is functionally significant.

K H Chang1, C Day, J Walker, T Hyypiä, G Stanway.   

Abstract

We have shown previously that, compared to other enteroviruses, the coxsackievirus A9 (CAV-9) prototype strain, Griggs, contains a C-terminal extension to the capsid protein VP1 and that within this extension there is an RGD (arginine-glycine-aspartic acid) motif. To determine whether these features are found in other CAV-9 strains and therefore analyse whether they are likely to be functionally important, we have determined the nucleotide sequence of the appropriate region from five strains, isolated over a 25 year period. The results indicate that there is considerable diversity between the strains and there is little correlation between nucleotide sequence identity and date of isolation. All isolates exhibit the VP1 extension and although its amino acid sequence is otherwise variable, the RGD motif is common to all. This conservation of sequence, within a region which can otherwise vary, implies that the RGD sequence must be functionally significant. The VP1 extension shows similarity to sequences found in foot-and-mouth-disease virus strains and to part of the precursor of the cellular protein, human transforming growth factor beta, and the possible significance of these observations is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312121     DOI: 10.1099/0022-1317-73-3-621

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Arginine-glycine-aspartic acid motif is critical for human parechovirus 1 entry.

Authors:  Y Boonyakiat; P J Hughes; F Ghazi; G Stanway
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 2.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  Analysis of a new human parechovirus allows the definition of parechovirus types and the identification of RNA structural domains.

Authors:  Mohammed Al-Sunaidi; Cigdem H Williams; Pamela J Hughes; David P Schnurr; Glyn Stanway
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

Review 4.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  An evolutionarily conserved splice generates a secreted env-Bet fusion protein during human foamy virus infection.

Authors:  M L Giron; H de Thé; A Saïb
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  The coxsackievirus A9 RGD motif is not essential for virus viability.

Authors:  P J Hughes; C Horsnell; T Hyypiä; G Stanway
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

Review 7.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

8.  Molecular and biological characteristics of echovirus 22, a representative of a new picornavirus group.

Authors:  G Stanway; N Kalkkinen; M Roivainen; F Ghazi; M Khan; M Smyth; O Meurman; T Hyypiä
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Equine herpesvirus 1 entry via endocytosis is facilitated by alphaV integrins and an RSD motif in glycoprotein D.

Authors:  Gerlinde R Van de Walle; Sarah T Peters; Brian C VanderVen; Dennis J O'Callaghan; Nikolaus Osterrieder
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

10.  A distinct picornavirus group identified by sequence analysis.

Authors:  T Hyypiä; C Horsnell; M Maaronen; M Khan; N Kalkkinen; P Auvinen; L Kinnunen; G Stanway
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.